نتایج جستجو برای: recurrent vulvovaginal candidiasis rvvc
تعداد نتایج: 137328 فیلتر نتایج به سال:
Abstract Background and purpose: Vulvovaginal candidiasis (VVC) often referred to as a yeast infection which is a common gynecologic problem, affecting %75 of women during their lifetimes. More than 40% of affected women will have two or more VVC episodes. Candida albicans is the most common agent of VVC however non-albicans Candida species have increasingly been identified as the cause of v...
Recurrent vulvovaginal candidiasis (RVVC) is seen in 5% of women with Candida vaginitis. Use of fluconazole as prophylactic treatment has been suggested for RVVC. The aim of the present study was to evaluate the efficacy of fluconazole suppressive therapy in RVVC patients, as a randomized, placebo-controlled, double-blind prophylactic study. Among the 330 women with acute symptomatic vulvovagin...
background: iron deficiency anemia (ida) has been controversially linked to il-4 production in previous studies. a predominant th1 response leads to resistance against recurrent vulvovaginal candidiasis (rvvc), whereas a th2 response exacerbates the disease. objective: to investigate the possible effect of iron deficiency on the host’s susceptibility to rvvc as a result of the th1/th2 cytokine ...
Vulvo-vaginal candidiasis (VVC) is a common infection among women. 5-8% of women with acute infection experience recurrent vulvo-vaginal candidiasis (RVVC). There is currently no gold standard treatment for RVVC. Although antifungal agents such as imidazoles have been successfully used as first-line treatment for acute VVC, the effectiveness of these medications is limited for RVVC, and various...
The ability to tolerate Candida albicans, a human commensal of the gastrointestinal tract and vagina, implicates that host defense mechanisms of resistance and tolerance cooperate to limit fungal burden and inflammation at the different body sites. We evaluated resistance and tolerance to the fungus in experimental and human vulvovaginal candidiasis (VVC) as well as in recurrent VVC (RVVC). Res...
BACKGROUND Available literature concerning the epidemiologic or clinical features of vulvovaginal candidiasis commonly reports that: 75% of women will experience an episode of vulvovaginal candidiasis in their lifetimes, 50% of whom will experience at least a second episode, and 5-10% of all women will experience recurrent vulvovaginal candidiasis (≥4 episodes/1 year). In this debate we traced ...
We studied host factors that could predispose women to develop recurrent vulvovaginal candidiasis (RVVC), including glycemia, insulin resistance, chronic stress, antioxidant capacity, overall immune status, local inflammation and vaginal microbiota. The presence of yeasts in vaginal culture was screened in 277 women, with or without signs and symptoms of VVC and RVVC. The presence of an inflamm...
Background: Looking at the increased incidence of recurrent vulvovaginal candidiasis and refractory resulting from such non-albicans Candida species in recent decades, this study was performed aiming the use of rapid biochemical and molecular detection of drug-resistant Candida species in response to fluconazole in patients with vulvovaginal candidiasis and recurrent vulvovaginal candidiasis. ...
Introduction: Recurrent Vulvovaginal Candidiasis (RVVC), which is mostly caused by Candida albicans (C. albicans), is the second common cause of genital tract infection in females. The purpose of this research was to identify Candida isolates from RVVC, identify predisposing factors and determine antifungal effect of fluconazole against Candida strains isolated from the patients. Methods: In...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید